Avobis Bio

Executive Summary

Avobis Bio is a clinical-stage biotechnology company pioneering implantable cell therapies for non-healing tissue conditions. Its proprietary platform combines mesenchymal stem cells (MSCs) with bioabsorbable materials to create a living implant that amplifies the body's natural healing processes. The lead product candidate, AVB-114, targets perianal fistulas in Crohn's Disease, a debilitating complication with limited treatment options. Unlike current therapies that manage symptoms, AVB-114 aims to achieve durable healing and potentially a cure. The company is based in San Diego and was founded in 2020, leveraging a robust scientific foundation and a clear unmet medical need. Avobis Bio's approach represents a significant advancement in regenerative medicine, offering a novel therapeutic modality that could transform the treatment paradigm for complex fistulizing diseases.

Upcoming Catalysts (preview)

• Q3 2026Phase 1/2 clinical trial data for AVB-11460% success
• Q4 2026Series B financing round70% success
• Q2 2026FDA Orphan Drug Designation or Fast Track for AVB-11450% success